Advertisement

Topics

GamaMabs licences AZ technology for new cancer therapy

07:28 EDT 10 Oct 2017 | PharmaTimes

French biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer.

Original Article: GamaMabs licences AZ technology for new cancer therapy

NEXT ARTICLE

More From BioPortfolio on "GamaMabs licences AZ technology for new cancer therapy"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...